Healthcare Industry News: Elekta
News Release - January 31, 2018
The Ottawa Hospital Acquires Several Elekta Versa HD Devices for Advanced Cancer TreatmentInnovative cancer treatment advancements on horizon for Ottawa patients
STOCKHOLM, Jan. 31, 2018 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST) announced today that it has signed a strategic agreement with The Ottawa Hospital (TOH) in Ottawa, Ontario, Canada to deliver several Elekta Versa HD™ linear accelerators as well as software support and services. The total value of the agreement is almost USD 29 million over eight years. Approximately USD 13 million will be booked in the third quarter of Elekta's 2017/18 fiscal year. The first Versa HD deliveries are scheduled for 2018.
More than 85,000 people are diagnosed with cancer in the province of Ontario each year; TOH treats 4,600 cases with radiation annually. Radiotherapy is recommended for more than half of all cancer cases. Versa HD is designed to be the most sophisticated, high-versatility treatment system, giving clinicians the flexibility to deliver conventional therapies to treat a wide range of small and large tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision.
Dr. Jason Pantarotto, MD, FRCPC, and Head of Radiation Oncology at The Ottawa Hospital, says, "Elekta's Versa HD linear accelerators will enable us to treat a broad spectrum of tumors throughout the body. The advanced technology will help us increase the use of high dose radiation treatments such as stereotactic body radiotherapy. These treatments reduce the total number of patient visits while improving clinical effectiveness."
Pete Gaccione, Elekta's Executive Vice President Region North America, says: "Elekta is proud to continue its established position as a major supplier of cancer treatment and neurosurgery systems. We share The Ottawa Hospital's vision to provide each patient with the world-class care. This agreement will provide thousands of patients at the hospital the opportunity to receive advanced cancer care."
To learn more about these solutions, visit www.Elekta.com
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on January 31, 2018. (REGMAR)
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.Elekta.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.